Skip to content
TrialScanner

NCT03761914

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Phase 1/Phase 2CompletedSLSLeadMRKCollaborator

Registry record

Lead sponsor
Sellas Life Sciences Group
Conditions
Acute Myelogenous Leukemia; Ovarian Cancer; Colorectal Cancer; Triple-negative Breast Cancer; Small-cell Lung Cancer
Primary completion
Jul 5, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03761914 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03761914: Galinpepimut-S in Combination... | TrialScanner